Moderna (MRNA.US) stock rose almost 6% after the drugmaker announced that its Covid-19 vaccine produced protective antibodies against the contagious delta variant. The mRNA vaccine produced neutralizing antibodies against all variants tested, including the delta, beta and eta, the company said in a statement. Additionally, news that India approved Moderna's vaccine for restricted emergency use also lifted sentiment towards the stock.
Moderna (MRNA.US) stock price rose sharply during today's session and hit a new all-time high at $238.22 which coincides with 127.2 external Fibonacci retracement. If the current sentiment prevails then the next target for bulls is located around $247.63 and is marked by 161.8 external Fibonacci retracement. Source: xStation5
Economic calendar: Key Macroeconomic Data from Europe and the US in Focus for Markets (05.11.2025)
Risk sentiment improves, but can the AI trade fully recover?
Morning Wrap (05.11.2025)
🚀 AMD Confirms AI Thesis with Strong Results and Confident Guidance
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
